Envita México

AAIT™ Cancer Treatment

Advanced Immunotherapy Using Your Own Immune Cells

AAIT™ (Autologous Adoptive Immunotherapy) is a form of adoptive cell transfer therapy designed to sustain lasting outcomes in cancer patients. This proprietary personalized precision oncology treatment combines advanced immunotherapies to help early stage, as well as late-stage cancer patients.

What is AAIT™?

AAIT™ treatment is rooted in the power of your own immune system, harnessing its natural strength to fight cancer cells more effectively. In this therapy, immune cells such as natural killer (NK) cells, dendritic cells, tumor-infiltrating lymphocytes, and cytotoxic T lymphocytes, are isolated from your body. These cells are then activated and expanded in number and conditioned in a laboratory setting, making them more effective in targeting and destroying cancer cells. The enhanced cells are then reintroduced into your body, aiming to improve your immune system's ability to combat cancer.

Personalized Immunotherapy to Target Various Types and Stages of Cancer

AAIT™ goes beyond standard cellular immunotherapies and cancer vaccines, which are currently being offered for certain specific types of cancers, to help a greater number of patients benefit from the latest developments in precision oncology. Our specially trained team personalizes this innovative immunotherapy to reactivate the immune system, which is the first and last line of defense against cancer.

Here is a step-by-step breakdown to explain how AAIT™ paves the way for a holistic and long-lasting recovery:


As the first step, an Apheresis unit collects white blood cells, including NK cells and dendritic cells, from your body.

Expansion and Activation

Using cytokines, which occur naturally within the body, these cells are expanded and activated over three to four weeks. This process not only increases the number of natural killer cells but also enhances their ability to fight the latest cancer mutations of each individual patient, which often gets overlooked in other standard oncology treatments. Personalization of AAIT™ allows the newly expanded cells to be ‘trained’ for fighting your cancer cells, using the freshest biopsy results.

Quality Testing

Before reintroduction, the expanded cells undergo rigorous testing for quantity, quality, and sterility, ensuring they are both numerous and effectively reactive against your tumor.


Billions of trained natural killer cells and dendritic cells are infused back into your body, with the aim of potentiating lasting outcomes.

Incorporates the Latest in Cancer Research

In clinical studies, adoptive cell transfer treatments which include the latest in cancer research, like AAIT™, have shown promise in improving clinical conditions and symptoms in patients. In our clinical experience of 25 years, this type of treatment has been well-tolerated and shown to be safe without causing any severe adverse effects. Latest research reports a reduction in circulating tumor cells following adoptive cell therapy [1]. 

How AAIT™ Overcomes the Challenges of Other Standard Immunotherapies

AAIT™ packs in the advantages of several other immunotherapies, making it a comprehensive treatment with the potential of life-changing results for cancer patients. The following features of AAIT™ make it stand out as compared to other standard cellular immunotherapies and cancer vaccines:

Comprehensive Immune Response

Combines NK cells and dendritic cells for a more effective treatment.

Personalized Treatment

Tailored specifically to your body and your cancer, utilizing your body’s own cells.

Synergistic Approach

Can be used alongside other cancer treatments to enhance overall efficacy.

While the category of adoptive cell therapy is in human clinical trials, it is not currently FDA approved in the United States [2]. This proprietary treatment developed by Envita Medical Centers is available exclusively at our Envita Mexico location, which follows the same standard operating procedures for quality assurance as our Arizona facility.


  1. Parsonidis, P., Beis, G., Iliopoulos, A. C., & Papasotiriou, I. (2022). Adoptive transfer of activated immune cells against solid tumors: A preliminary study. Cellular Immunology, 382, 104616–104616. https://doi.org/10.1016/j.cellimm.2022.104616.
  2. Folsom, T. D., Moriarity, B. S., Starr, T. K., Lou, E., & Webber, B. R. (2022). Tumor-infiltrating lymphocytes: Prognostic considerations and current trials as adoptive cell therapy. In NK Cells in Cancer Immunotherapy: Successes and Challenges (pp. 403–426). Elsevier. https://doi.org/10.1016/B978-0-12-822620-9.00005-7.

Disclaimer: The information on this website is for educational purposes only and not intended as medical advice. Always consult with a qualified healthcare provider for medical advice and treatment options.

Choose Envita Medical Centers

Would you like to learn more about treatment options? Send us a message and we will be in touch shortly or call 1-866-830-4576.

Personal Information

Enter your date of birth.

Contact Preferences